Payment overview · 2025
General Payments
$229.50
6 reported records · 3 companies
Healthcare provider profile · identity verified
David Michael Harris, MD
Allopathic & Osteopathic Physicians|Family Medicine · ROYSTON, GA · NPI 1619035169
Verified facts
What the public records show
CMS Open Payments records show David Michael Harris, MD received $229.50 in general payments during 2025 across 6 reported records.
Stryker Corporation accounted for 65.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $149.45 | 65.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.03 | 28.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.02 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $229.50 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION Normalized: blueprint patient specific instrumentation |
Device | Stryker Corporation | $149.45 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.92 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.02 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.49 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 741 | 173 |
| Atorvastatin Calcium | Atorvastatin Calcium | 690 | 168 |
| Levothyroxine Sodium | Levothyroxine Sodium | 681 | 139 |
| Clonazepam | Clonazepam | 598 | 102 |
| Gabapentin | Gabapentin | 563 | 105 |
| Hydrochlorothiazide | Hydrochlorothiazide | 543 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 495 | 117 |
| Metformin Hcl | Metformin Hcl | 495 | 117 |
| Tramadol Hcl | Tramadol Hcl | 477 | 78 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 450 | 52 |
| Furosemide | Furosemide | 437 | 65 |
| Potassium Chloride | Potassium Chloride | 430 | 50 |
| Omeprazole | Omeprazole | 423 | 92 |
| Famotidine | Famotidine | 396 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 371 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 337 | 43 |
| Simvastatin | Simvastatin | 331 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 324 | 78 |
| Donepezil Hcl | Donepezil Hcl | 311 | 52 |
| Losartan Potassium | Losartan Potassium | 309 | 72 |
| Alprazolam | Alprazolam | 301 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 273 | 70 |
| Alendronate Sodium | Alendronate Sodium | 255 | 43 |
| Memantine Hcl | Memantine Hcl | 253 | 38 |
| Trazodone Hcl | Trazodone Hcl | 232 | 44 |
| Sertraline Hcl | Sertraline Hcl | 212 | 48 |
| Carvedilol | Carvedilol | 207 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 204 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 198 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 198 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 190 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 187 | 33 |
| Allopurinol | Allopurinol | 186 | 47 |
| Eliquis | Apixaban | 180 | 25 |
| Azithromycin | Azithromycin | 164 | 137 |
| Glipizide Er | Glipizide | 161 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 160 | 40 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 147 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 142 | 31 |
| Meloxicam | Meloxicam | 141 | 37 |
| Memantine Hcl Er | Memantine Hcl | 139 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 31 |
| Montelukast Sodium | Montelukast Sodium | 124 | 33 |
| Finasteride | Finasteride | 117 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 115 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 112 | 87 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 36 |
| Spironolactone | Spironolactone | 111 | 15 |
| Lovastatin | Lovastatin | 107 | 23 |
| Januvia | Sitagliptin Phosphate | 103 | 11 |
| Glipizide | Glipizide | 92 | 32 |
| Buspirone Hcl | Buspirone Hcl | 91 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 91 | suppressed |
| Aripiprazole | Aripiprazole | 87 | suppressed |
| Prednisone | Prednisone | 87 | 69 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 85 | 78 |
| Doxazosin Mesylate | Doxazosin Mesylate | 78 | 17 |
| Ozempic | Semaglutide | 78 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 77 | 17 |
| Ezetimibe | Ezetimibe | 77 | 19 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 74 | 18 |
| Estradiol | Estradiol | 72 | 19 |
| Lorazepam | Lorazepam | 72 | 11 |
| Torsemide | Torsemide | 72 | suppressed |
| Mirtazapine | Mirtazapine | 71 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 70 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 70 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 69 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 68 | 57 |
| Pregabalin | Pregabalin | 67 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 66 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 17 |
| Digoxin | Digoxin | 64 | suppressed |
| Fenofibrate | Fenofibrate | 64 | suppressed |
| Atenolol | Atenolol | 63 | 16 |
| Cefdinir | Cefdinir | 63 | 53 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 14 |
| Venlafaxine Hcl | Venlafaxine Hcl | 55 | suppressed |
| Fluconazole | Fluconazole | 54 | 38 |
| Tresiba Flextouch U-100 | Insulin Degludec | 54 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 11 |
| Synthroid | Levothyroxine Sodium | 53 | 14 |
| Risedronate Sodium | Risedronate Sodium | 51 | suppressed |
| Linzess | Linaclotide | 50 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 50 | 11 |
| Bupropion Xl | Bupropion Hcl | 49 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 47 | suppressed |
| Propylthiouracil | Propylthiouracil | 47 | suppressed |
| Celecoxib | Celecoxib | 46 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 46 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 46 | suppressed |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 42 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 42 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 41 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 39 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Diazepam | Diazepam | 37 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Jardiance | Empagliflozin | 32 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 32 | suppressed |
| Risperidone | Risperidone | 32 | suppressed |
| Acarbose | Acarbose | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 21 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Latanoprost | Latanoprost | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Cephalexin | Cephalexin | 28 | 25 |
| Methimazole | Methimazole | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Levemir | Insulin Detemir | 27 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 19 |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 11 |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 19 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 18 | 14 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 17 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Metronidazole | Metronidazole | 12 | 12 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $229.50 · 6 records | Stryker Corporation | AIRSUPRA, BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION, Ozempic, Rybelsus, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error